GH stock forecast, quote, news & analysis
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use... Show more
Guardant Health (GH) Stock Analysis: Shield Coverage Expansion Meets Pre-Earnings Consolidation
Key Takeaways
- Guardant Health shares traded near $145.53 in late July 2026, consolidating after a sharp rally driven by UnitedHealth's decision to cover the Shield colorectal cancer blood test.
- The stock surged roughly 20% in early July following the insurer coverage announcement but has since pulled back approximately 16% from its 52-week high of $174.08.
- Q1 2026 revenue grew 48% year-over-year to $301.7 million, and management raised full-year 2026 revenue guidance to $1.30–$1.32 billion.
- Q2 2026 earnings are scheduled for July 30, 2026, with analysts projecting approximately $314 million in revenue and a loss of roughly $0.75 per share.
- Insider selling by co-CEOs and other executives has drawn attention, with over $90 million in insider sales over the last 90 days.
- Wall Street analysts remain broadly bullish, with price targets ranging from $127 to $215 and a consensus "Moderate Buy" rating.
Current Market Snapshot
Guardant Health (GH) shares have experienced a volatile few weeks, characterized by a powerful rally followed by a measured pullback. The stock rocketed nearly 20% in the first week of July after UnitedHealth Group confirmed it would cover Shield — Guardant's blood-based colorectal cancer screening test — for millions of its members beginning August 1, 2026. The news sent GH to a 52-week high of $174.08. Since that peak, however, the stock has given back ground, retreating toward the $145 area as investors booked profits, digested insider selling activity, and repositioned ahead of the company's upcoming second-quarter earnings report. The broader oncology diagnostics sector remains in focus, and Guardant's liquid biopsy portfolio continues to attract institutional interest, with over 92% of shares held by institutions.
Guardant Health (GH) Business Overview and Competitive Position
Guardant Health is a precision oncology company headquartered in Palo Alto, California, that specializes in blood-based and tissue-based cancer diagnostics. Founded in 2012, the company has built a comprehensive testing portfolio that spans the cancer care continuum — from early screening to treatment selection and recurrence monitoring. Its flagship product, Guardant360, is a liquid biopsy test that profiles genomic alterations in patients with advanced solid tumors using a simple blood draw. The company also offers Guardant Reveal for molecular residual disease testing and Guardant360 Tissue for tissue-based genomic profiling. Shield, its blood-based colorectal cancer screening test for average-risk adults aged 45 and older, represents Guardant's most significant growth opportunity. With FDA approvals, inclusion in American Cancer Society screening guidelines, and expanding commercial insurance coverage — most notably from UNH — Guardant is positioned at the intersection of oncology diagnostics, AI-driven data analytics, and large-scale population screening.
Recent Developments Driving GH
The single most impactful event for GH in recent weeks was UnitedHealth's July 1, 2026 announcement that it would cover Shield as a first-line colorectal cancer screening option for members aged 45 to 75. Analysts at Bernstein estimated the decision gives Guardant access to roughly 10 million newly reimbursed customers and nearly doubled their 2030 Shield revenue estimate from $770 million to approximately $1.5 billion. BTIG raised its price target from $160 to $190, noting the decision arrived one to two years earlier than expected. Bernstein subsequently raised its target to $200, and Citigroup lifted its target to $215.
On the regulatory front, the FDA recently approved an expanded Guardant360 CDx panel, and the American Cancer Society formally included Shield in its colorectal cancer screening guidelines. Guardant also graduated into the Russell 1000 index during June's annual reconstitution. These milestones were tempered by insider selling: co-CEO AmirAli Talasaz sold over $21 million in shares, and co-CEO Helmy Eltoukhy sold approximately $12.6 million, both executed under pre-arranged Rule 10b5-1 trading plans. Combined with other executive sales, insider dispositions totaled more than $90 million over the trailing 90 days — a factor that contributed to the stock's pullback from its July highs as investors reassessed near-term risk-reward.
Trending AI Robots
For investors seeking data-driven approaches to navigate stocks like Guardant Health, Tickeron's Trending AI Robots page offers a curated view into AI-powered trading strategies. Tickeron hosts hundreds of AI trading bots that actively trade thousands of tickers across diverse strategies and timeframes. The Trending AI Robots section highlights only the top-performing and most relevant bots, allowing users to filter by performance metrics, trading style, and risk parameters. Each bot operates with a distinct methodology — from swing trading to longer-term trend following — giving traders visibility into algorithms that have demonstrated consistency in real market conditions. Exploring this section can complement traditional research by showcasing how quantitative models interpret price action and market signals in real time.
2026 Outlook and What Investors Should Watch
The most immediate catalyst for GH is the Q2 2026 earnings report scheduled for July 30, 2026. Investors will closely monitor Shield test volumes, updates on commercial insurer coverage expansion following the UnitedHealth decision, and any signs that operating losses are narrowing as revenue scales. The company's full-year guidance of $1.30–$1.32 billion in revenue implies 32–34% growth, and management has targeted company-wide cash flow breakeven by the end of 2027. Additional commercial insurers are expected to follow UnitedHealth's lead in covering Shield over the coming quarters, and a formal recommendation from the U.S. Preventive Services Task Force (USPSTF) would further expand the addressable market. On the risk side, Guardant remains unprofitable on a GAAP basis — Q1 2026 net loss widened to $112.1 million — and the stock trades at a substantial premium to many intrinsic valuation models. Competition from EXAS in stool-based screening and ongoing cash burn remain key considerations for investors evaluating the risk-reward profile heading into the second half of 2026.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for GH shows an upward move is likely
GH's Aroon Indicator triggered a bullish signal on July 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 191 similar instances where the Aroon Indicator showed a similar pattern. In of the 191 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for GH moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GH as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for GH turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GH broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GH's P/B Ratio (60.976) is slightly higher than the industry average of (13.310). P/E Ratio (0.000) is within average values for comparable stocks, (150.963). GH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.685). GH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (17.361) is also within normal values, averaging (8.171).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of diagnostic technologies to improve cancer management
Industry MedicalSpecialties